bims-midomi Biomed News
on MDM2 and mitochondria
Issue of 2026–04–05
two papers selected by
Gavin McStay, Liverpool John Moores University
  1. Longitudinal Profiling of Cervical Cancers Reveals Therapy-Induced Vulnerabilities Beyond the Checkpoint.
  2. Unlocking the Anticancer Potential of New Spirooxindoles via p53-MDM2/MDMX Dual Inhibition: In Vitro and In Silico Assessments.
  1. Cancer Res. 2026 Apr 02. 86(7): 1540-1542
    Longitudinal Profiling of Cervical Cancers Reveals Therapy-Induced Vulnerabilities Beyond the Checkpoint.
    Ann H Klopp.
      Although some patients with cervical cancer respond well to therapy, others show minimal response and develop recurrence after treatment. A better understanding of the molecular features that distinguish and drive the variable responses to therapy is needed to improve patient stratification and treatment. In this issue of Cancer Research, Sandoval and colleagues conduct integrated multiomic analyses of longitudinal patient cohorts to characterize the molecular and cellular reprogramming induced by chemoradiation therapy (CRT). The analyses show that treatment fundamentally reshapes the tumor microenvironment, inducing a shift from lymphoid-dominant to myeloid-dominant immune infiltration. The authors also identify the induction of MDM2-dependent DNA damage response specifically in tumor cells. Leveraging both treatment-naïve and CRT-exposed patient-derived xenografts, they demonstrate that MDM2 inhibition enhances radiation response, with the greatest efficacy in therapy-resistant tumors. These findings identify MDM2 as a rational, therapy-induced target emerging from unbiased analysis. As the field moves toward integrating targeted therapies and immunotherapy with standard chemoradiation, this study underscores the importance of understanding when, where, and in whom to intervene. See related article by Sandoval et al., p. 1639.
    DOI:  https://doi.org/10.1158/0008-5472.CAN-25-5767
  2. Drug Dev Res. 2026 Apr;87(2): e70277
    Unlocking the Anticancer Potential of New Spirooxindoles via p53-MDM2/MDMX Dual Inhibition: In Vitro and In Silico Assessments.
    Haidy H El-Zoheiry, Rehab F Ahmed, Mahmoud S Elkotamy, Hatem A Abdel-Aziz, Ghada F Elmasry.
      Blocking the p53-MDM2 and/or p53-MDMX protein-protein interaction (PPI) by small-molecule inhibitors has been tracked as a potentially effective cancer treatment approach. Herein, we present the discovery of a new series of spirooxindole-tethered pyrazolopyridine derivatives. The development of the new congeners was based on the analysis of the co-crystal structures of the inhibitors bound to both MDM2 and MDMX and studying the binding interactions between the substituents of small molecules and the three subpockets of the p53-MDM2/MDMX. The spirooxindoles 6b, 6k, and 6n attained the most pronounced activity in the MULTI-ARRAY MDM2-p53 complex assay with IC50 values of 1.26, 1.30, and 1.25 µM, respectively, in comparison with nutlin-3 (IC50 = 2.03 µM). The counterparts 6b, 6k, and 6n also revealed notable inhibitory potential against p53-MDMX. The antiproliferative efficacy of the most active target compounds was assessed in HCT-116 colon cancer cell line that overexpressed MDM2 and harbored wild-type p53. The derivative 6k accomplished the highest antiproliferative activity against HCT-116 compared to nutlin-3. Moreover, 6k displayed minimal toxicity compared to the reference nutlin-3 when examined on a normal cell line. Flow cytometric analysis revealed that 6k controlled cell growth via cell cycle arrest at the G1 phase and induced cell death via apoptosis. Additionally, compound 6k revealed a prominent effect in raising p53 levels with a 6.464-fold increase compared to the control. Molecular docking and molecular dynamics simulations justified the observed efficacy. Collectively, this study showcased a new class of potent p53-MDM2/MDMX dual inhibitors possessing a spirooxindole scaffold which can be subjected to future development.
    Keywords:  anticancer; p53‐MDM2; pyrazolopyridines; spirooxindoles
    DOI:  https://doi.org/10.1002/ddr.70277
This page is being maintained by Thomas Krichel. It was last updated on 2026‒04‒06 at 20:25.